The document discusses randomized controlled trials (RCTs). It summarizes that HSRU is funded by the Scottish Government Health Directorates, and the author accepts full responsibility for the talk. RCTs are the gold standard for evaluating healthcare interventions through random allocation of participants to experimental or control groups in order to minimize bias.
Bias, confounding and causality in p'coepidemiological researchsamthamby79
A brief description of three issues (Bias, Confounding and Causality) commonly encountered while performing pharmacoepidemiological research. A big THANK YOU to Mr. Strom and Mr. Kimmel.
Bias, confounding and causality in p'coepidemiological researchsamthamby79
A brief description of three issues (Bias, Confounding and Causality) commonly encountered while performing pharmacoepidemiological research. A big THANK YOU to Mr. Strom and Mr. Kimmel.
An epidemiological experiment in which subjects in a population are randomly allocated into groups, usually called study and control groups to receive and not receive an experimental preventive or therapetuic procedure, maneuver, or intervention .
Randomization is the process by which allocation of subjects to treatment groups is done by chance, without the ability to predict who is in what group. It is done in clinical trials. This presentation describes the methods of randmization used in clinical trials.
Study designs, Epidemiological study design, Types of studiesDr Lipilekha Patnaik
Study design, Epidemiological study designA study design is a specific plan or protocol
for conducting the study, which allows the investigator to translate the conceptual hypothesis into an operational one.
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershmanbkling
Dr. Dawn L. Hershman of the Herbert Irving Comprehensive Cancer Center at Columbia University presented the basics of clinical trials and emphasized how important it is for more patients to participate in them. She also discussed trials currently available for early stage and metastatic breast cancers. The webinar was presented on June 25, 2014. To hear the webinar, visit www.sharecancersupport.org/hershman
An epidemiological experiment in which subjects in a population are randomly allocated into groups, usually called study and control groups to receive and not receive an experimental preventive or therapetuic procedure, maneuver, or intervention .
Randomization is the process by which allocation of subjects to treatment groups is done by chance, without the ability to predict who is in what group. It is done in clinical trials. This presentation describes the methods of randmization used in clinical trials.
Study designs, Epidemiological study design, Types of studiesDr Lipilekha Patnaik
Study design, Epidemiological study designA study design is a specific plan or protocol
for conducting the study, which allows the investigator to translate the conceptual hypothesis into an operational one.
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershmanbkling
Dr. Dawn L. Hershman of the Herbert Irving Comprehensive Cancer Center at Columbia University presented the basics of clinical trials and emphasized how important it is for more patients to participate in them. She also discussed trials currently available for early stage and metastatic breast cancers. The webinar was presented on June 25, 2014. To hear the webinar, visit www.sharecancersupport.org/hershman
MedicReS Winter School 2017 Vienna - Importance of Selection of Outcomes - Ma...MedicReS
Importance of Selection of Outcomes and Covariates in Comparative Effectiveness of Cancer ...
International Conference Good Biostatistical and Publication Practice in Cancer Research with “Real Work Data”
February 13-14th, Vienna
Mariana Chavez Mac GregorMD, MSc.
Assistant Professor, Health Services Research Department
Breast Medical Oncology Department
Vinay Prassad, hematólogo-oncólogo y profesor de Medicina en la Oregon Health and Sciences University. Ponencia presentada en el marco de la jornada Cómo revertir prácticas clínicas de escaso valor organizada por la Societat Catalana de Gestió Sanitària el 18 de mayo de 2018.
Steps in conducting a RCT
1. Drawing up a protocol
2. Selecting Reference & Experimental population
3. Randomization
4. Manipulation or Intervention
5. Follow up
6. Assessment of outcome
1. Drawing up a protocol
Aims and objectives of the study
Questions to be answered
Criteria for the selection of study and control groups
Size of the sample & allocation of subjects in both groups
Treatment to be applied - when, where, how
Standardization of working procedures and
Schedules as well as responsibilities of persons involved in the trial up to the stage of evaluation of outcome of the study.
2. Selecting Reference and Experimental Populations
Reference or target population - Population to which the findings of the trial, if found successful, are expected to be applicable (Eg: drugs, vaccines, etc.)
Experimental or Study population
Derived from the Reference population
Has same characteristics as the Reference population
Actual population that participates in the experimental study
Must give informed consent - Should be qualified or eligible for the trial
3. Randomization
Heart of the control trial
Procedure:
Participants are allocated into study and control groups
Eliminates bias and allows comparability
By random allocation every individual gets an equal chance for being allocated in to either groups.
4. Manipulation/ Intervention
Having formed the study and control group, the next step is to intervene or manipulate the study (experimental) group by deliberate application or withdrawal or reduction of a suspected causal factor
Eg: Drug, Vaccine, Dietary component, a habit
5. Follow up
Implies examination of the experimental and control group subjects at defined intervals of time in a standard manner, with equal intensity, under the same given circumstances in the same time frame till final assessment of outcome.
Attrition:
Inevitable losses to follow up (death, migration, loss of interest)
6. Assessment
a. Positive results:
Reduced incidence or severity of disease
Reduced cost to health service
Appropriate outcome in the study
b. Negative results:
Increased severity or frequency of side effects
Complications
Deaths
BIAS:
Any systematic error in the determination of association and outcome.
Bias may arise from errors of assessment of outcome due to human element
Subjective bias
Observer bias
Evaluation bias
1. Subjective Bias:
Participants, subjectively feel better or report improvement if they knew they were receiving a new form of treatment. This is known as “Subject variation”.
2. Observer Bias:
Investigator measuring the outcome of a therapeutic trial may be influenced if he knows beforehand the particular procedure or therapy to which the patient has been subjected.
3. Evaluation Bias:
Investigator may subconsciously give a favorable report of the outcome of the trial.
Blinding:
1. Single Blind Trial: Participant
2. Double Blind: Partcipant + Investigator
3. Triple Blind: Participant + Investigator + Data Analyzer
The scientific study of methods to promote the systematic uptake of research findings and other evidence-based practices into routine practice and hence improve the quality and effectiveness of health services
The randomised control trial (RCT) is a trial in which subjects are randomly assigned to one of two groups: one (the experimental group) receiving the intervention that is being tested, and the other (the comparison group or control) receiving an alternative (conventional) treatment
Intervista a Eugenio Santoro e Giuseppe Recchia su Il Corriere Innovazioni di Simona a cura di Simona Regina. Digital health, digital therapeutics, app. Quali regole per affidarsi a tali strumenti, come, studiarli, come dimostrarne la validità e l'efficacia, come regolamentarli.
Il ruolo del web nella ricerca di informazioni sulla salute, Isabella Cecchin...Eugenio Santoro
Intervento di Isabella Cecchini al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
La disinformazione corre sui social? Walter Quattrociocchi 24 maggio 2016 #sa...Eugenio Santoro
Intervento di Walter Quattrociocchi al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
La comunicazione e la promozione della salute sui social media: esistono evid...Eugenio Santoro
Intervento di Eugenio Santoro al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
Social Media e istituzioni sanitarie, Alessandro Lovari 24 maggio 2016 #salut...Eugenio Santoro
Intervento di Alessandro Lovari al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
La comunicazione social tra i pazienti, Roberto Ascione 24 maggio 2016 #salut...Eugenio Santoro
Intervento di Roberto Ascione al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
La partecipazione e l’empowerment del paziente, Paola Mosconi 24 maggio 2016 ...Eugenio Santoro
Intervento di Paola Mosconi al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
Dall’empowerment all’engagement del paziente, Guendalina Graffigna 24 maggio ...Eugenio Santoro
Intervento di guendalina Graffigna al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016
http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
Rivoluzione digitale e medicina narrativa - Cristina Cenci, 24 maggio 2016 #s...Eugenio Santoro
Intervento di Cristina Cenci al convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016 http://www.marionegri.it/it_IT/home/archivio_news_focus/archivio_news/News_2016/Comunicare+e+promuovere+la+salute+ai+tempi+dei+social+media/135852,News.html
Programma definitivo convegno Comunicare e promuovere la Salute ai Tempi dei ...Eugenio Santoro
Programma definitivo del convegno Comunicare e promuovere la Salute ai Tempi dei Social Media #salutesocial, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 24 maggio 2016
La comunicazione e la promozione della salute sui nuovi media: è solo moda o ...Eugenio Santoro
Diapositive di Eugenio Santoro presentate il 6 novembre 2015 al convegno salute 2.0 - informazione, comunicazione e cronaca sulla salute" organizzato da Regione Emilia Romagna e Pubblicità Progresso. Titolo della relazione "La comunicazione e la promozione della salute sui nuovi media: è solo moda o esistono evidenze scientifiche?"
Mobile health e applicazioni per la salute: aspetti regolatori e suggerimentiEugenio Santoro
Diapositive di Eugenio Santoro presentate all'Italian Digital Health Summit di Aboutpharma del 16 giugno 2015. Aspetti regolari (FDA), espetti etici (Comitato Nazionale di Bioetica) e suggerimenti (Mario Negri e Innova Fiducia) sull'uso delle applicazioni per smartphone in sanità.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
Randomized controlled trial
1. HSRU is funded by the Chief Scientist Office of the Scottish
Government Health Directorates . The author accepts full
responsibility for this talk.
Health Services Research Unit
University of Aberdeen
Randomised ControlledRandomised Controlled
Trials (RCTs)Trials (RCTs)
Graeme MacLennan
2. Health Services Research Unit
James LindJames Lind
• Born Edinburgh 1716
• On HMS Salisbury in 1747 he
allocated 12 men with scurvy
– Cider
– Seawater
– Horseradish, mustard, garlic
– Nutmeg
– Elixir Vitriol
– Oranges and Limes
3. Health Services Research Unit
Think about…Think about…
• Consider how you would go about evaluating the
following interventions
– Surgical versus medical termination of pregnancy
– Referral guidelines for radiographic examination
– Paracetamol and/or ibuprofen for treating children
with fever
– Nurse counsellors as an alternative to clinical
geneticists for genetic counselling
– Single dose of chemotherapy versus radiotherapy
treating testicular cancer
http://news.bbc.co.uk/1/hi/health/7647007.stm
– Cervical cancer vaccine
http://news.bbc.co.uk/1/hi/health/6223000.stm
4. Health Services Research Unit
The need to evaluate healthThe need to evaluate health
carecare
• Variations in health care
• Unproven treatments
• Inadequacies in care
• Inaccurate medical models
• Limitation of resources
• New innovations
• …
Crombie (1996)
5. Health Services Research Unit
Evaluation processEvaluation process
• Define research question
• What is already known?
• Identify appropriate study design
• Define population, intervention and criteria for
evaluation
• How large a study?
• Consider measurement of evaluation criteria
(“outcomes”)
– How often?
– Timing? Length of follow up?
– To whom? Who collects the data? What format?
• Analysis of data
• Dissemination and implementation
6. Health Services Research Unit
Define research question andDefine research question and
what is already knownwhat is already known
• Research question (PICOT)
– Population
– Intervention
– Control/comparator
– Outcome
– Target
• Has the question already been answered?
– Conduct review to assess what is know
about intervention
7. Health Services Research Unit
Definition of population,Definition of population,
intervention and “outcomes”intervention and “outcomes”
• Population
– Strict definition (explanatory) or flexible
(pragmatic)
• Intervention
– Dose of drug, timing etc
• “Outcomes”
– Health related Quality of Life
– Biochemical outcomes
– Symptoms
– Physical assessment
– Patient satisfaction
– Acceptability
– Cost-effectiveness
8. Health Services Research Unit
Measuring “outcome”Measuring “outcome”
• Questionnaires, interview, medical
notes etc
• Timing of questionnaires?
– Baseline (prior to treatment)
– Short term outcomes
– Long term outcomes
• Who collects the data?
9. Health Services Research Unit
Sources of systematicSources of systematic
errorserrors
• Selection bias
– can be introduced by the way in which comparison
groups are assembled
• Attrition bias
– systematic differences in withdrawal/follow up
• Performance bias
– Systematic differences in care provided
• Observation/detection bias
– systematic differences in observation,
measurement, assessment
10. Health Services Research Unit
What is a randomised controlled trial?What is a randomised controlled trial?
Simple Definition
• A study in which people are allocated
at random to receive one of several
interventions
(simple but powerful research tool)
11. Health Services Research Unit
Simple RCT modelSimple RCT model
Trial participantsTrial participants
RANDOMLYRANDOMLY allocatedallocated
to experimentalto experimental
oror CONTROLCONTROL groupgroup
CONTROLCONTROLEXPERIMENTEXPERIMENT
12. Health Services Research Unit
What is aWhat is a randomisedrandomised controlled trial?controlled trial?
• Random allocation to intervention
groups
• all participants have equal chance of
being allocated to each intervention
group
why RCTs are referred to as
randomised controlled trials
13. Health Services Research Unit
TerminologyTerminology
• Interventions are comparative regimes within
a trial
• Prophylactic, diagnostic, therapeutic e.g.
– preventative strategies
– screening programmes
– diagnostic tests
– drugs
– surgical techniques
14. Health Services Research Unit
What is a randomisedWhat is a randomised
controlledcontrolled trial?trial?
• One intervention is regarded as
control treatment (the group of
participants who receive this are the
control group)
• NOTE: Contemporaneous (not
historical controls)
why RCTs are referred to as randomised
controlled trials
15. Health Services Research Unit
TerminologyTerminology
Control Group
• can be
– conventional
practice
– no intervention
(this may be
conventional
practice)
– placebo
Experimental
Group
• receive new
intervention
• (also called
treatment group or
intervention group
interchangeably)
16. Health Services Research Unit
What is aWhat is a randomisedrandomised
controlled trialcontrolled trial ??
• RCTs are
– Experiments: investigators can influence
number, type, regime of interventions
– Quantitative: measure events rather than
try to interpret them in their natural
settings
– Comparative: compare two or more
interventions
17. Health Services Research Unit
What is a randomisedWhat is a randomised
controlled trial?controlled trial?
More Complex Definition
• Quantitative, comparative, controlled
experiments in which a group of
investigators study two or more
interventions in a series of participants
who are allocated randomly to each
intervention group
18. Health Services Research Unit
Inclusion/exclusion criteriaInclusion/exclusion criteria
• Decision rules applied to potential trial
participants to judge eligibility for
inclusion in trial
• See CONSORT statement
www.consort-statement.org
• Important that they are applied
identically to all groups in a trial!
19. Health Services Research Unit
What is randomisation?What is randomisation?
• Randomisation is the process of random
allocation
• Allocation is not determined by investigators,
clinicians or participants
• Equal chance of being assigned to each
intervention group
• Individual people
– patients
– caregivers (physicians, nurses etc)
• Groups of people, ‘cluster randomisation’
• (Covered in more depth in later lecture)
20. Health Services Research Unit
Pseudo-randomisationPseudo-randomisation
• Other allocation methods include
– according to date of birth
– the number on hospital records
– date of invitation etc.
• These are NOT regarded as random
• These are called pseudo- or quasi-
random
21. Health Services Research Unit
TerminologyTerminology
• Controlled clinical trials (CCTs) are
not the same as randomised controlled
trials
• Controlled clinical trials include non-
randomised controlled trials and
randomised controlled trials
22. Health Services Research Unit
Why use randomisation?Why use randomisation?
• Characteristics similar across groups at
baseline
• can isolate and quantify impact of
interventions with effects from other
factors minimised
• Risk of imbalance not abolished
completely even if perfect randomisation
• To combat selection bias
Unpredictability paradox: review of empirical comparisons of randomised and non-randomised
clinical trials, Kunz and Oxman 1998 BMJ
http://www.bmj.com/cgi/content/abstract/317/7167/1185
23. Health Services Research Unit
Why do we need a control group?Why do we need a control group?
• Don’t need a control group if
completely predictable results
– Parachutes when jumping from
plane
– New drug cures a few rabies cases
• But
– No intervention has 100% efficacy
– Many diseases recover
spontaneously
24. Health Services Research Unit
Regression to the meanRegression to the mean
• Occurs when an intervention aimed at
a group or characteristic that is very
different from average
• For example selecting people because
they have high blood pressure then
measuring them in future will see the
blood pressure measurements closer
to the mean of the population
Morton and Torgerson BMJ 2003 326:1083-4
Bland and Altman BMJ 1994 308:1499 and 309:780
25. Health Services Research Unit
DISTRIBUTION OFDISTRIBUTION OF
RESULTSRESULTS
threshold
measurement 1measurement 2
26. Health Services Research Unit
Hawthorne EffectHawthorne Effect
• Experimental effect in the direction
expected but not for the reason
expected
• Essentially studying/measuring
something can change what you
studying/measuring
27. Health Services Research Unit
Placebo EffectPlacebo Effect
• Effect (usually, but not always positive)
attributed to the expectation that a therapy
will have an effect
• The effect is due to the power of suggestion
• A placebo is an inert medication or
procedure
Waber et al 2008 JAMA Commercial Features of Placebo and
Therapeutic Efficacy
http://jama.ama-assn.org/cgi/content/full/299/9/1016
28. Effect size
Experimental group Control group
Hawthorne E.
R. mean
Placebo E.
Therapeutic E.
Real difference
Noise
Signal
EFFECT OF ANEFFECT OF AN
INTERVENTIONINTERVENTION
29. Health Services Research Unit
Minimising bias in RCTsMinimising bias in RCTs
• Blinding
– Single blind – participants are unaware of
treatment allocation
– Double blind – both participants and
investigators are unaware of treatment
allocation
– Requires use of placebos in drug trials
Schulz and Grimes (2002)
30. Health Services Research Unit
Concealment of random allocation listConcealment of random allocation list
• “Trials with inadequate allocation
concealment have been associated with
larger treatment effects compared with
trials in which authors reported adequate
allocation concealment”
Schulz KF (1995). Subverting randomisation in
controlled trials. JAMA, 274, 1456-8
31. Health Services Research Unit
Blinding, placebosBlinding, placebos
• RCTs should use the maximum degree of
blinding that is possible
• Placebo is a ‘dummy’ treatment given
when there is no obvious standard
treatment
– needed as the act of taking a treatment
may have some effect -need to
attribute
– double blind treatments must be
indistinguishable to those affected
32. Health Services Research Unit
Empirical evidence ofEmpirical evidence of
biasbias
MethodologicalIssue Increaseintreatment
effect(OR)
Inadequateconcealment of
treatmentallocation
41%
Unclearmethodofconcealment
oftreatmentallocation
30%
Trialnotblinded(whencould
havebeen)
17%
SchulzKFetal.JAMA1995;273:408-412
33. Health Services Research Unit
‘‘Explanatory’ and ‘Pragmatic’Explanatory’ and ‘Pragmatic’
questionsquestions
Explanatory
• Can it work in an
ideal setting …..?
• Efficacy
• Hypothesis testing
• Placebo controlled
• Double blind
Pragmatic
• Does it work in the real
world …..?
• Effectiveness
• Choice between
alternative approaches
to health care
• Standard care
• Open
34. Health Services Research Unit
Key differences betweenKey differences between
explanatory and pragmatic trialsexplanatory and pragmatic trials
(1)(1)
Explanatory Pragmatic
Question efficacy effectiveness
Setting ‘laboratory’ normal practice
Participants strictly defined broader, clinically indicated
(uncertainty)
Interventions strictly defined as clinical practice
35. Health Services Research Unit
Key differences betweenKey differences between
explanatory and pragmatic trialsexplanatory and pragmatic trials
(2)(2)
Explanatory Pragmatic
Outcomes short-term long-term, patient-
surrogates centered and
resource orientated
Size small (usually larger
single centre) (often multi-centre)
Analysis treatment received intention to treat
Relevance indirect direct
to practice
36. Health Services Research Unit
Example of selection biasExample of selection bias
for PP in an open trialfor PP in an open trial
Worse prognosisWorse prognosis
ExEx
pp
CtrlCtrl
None
None
White(2005)
E
E
37. Health Services Research Unit
Terminology: explanatoryTerminology: explanatory
versus pragmaticversus pragmatic
• Explanatory trials
– estimates efficacy - that is the benefit the
treatment produces under ideal conditions
• Pragmatic trials
– estimates effectiveness - that is the
benefit the treatment produces under
routine clinical practice
Roland M, Torgerson D. What are pragmatic trials? BMJ
1998;316:285
38. Health Services Research Unit
RCT as the GoldRCT as the Gold
StandardStandard
• The randomised controlled trial is
widely regarded as the gold standard
for evaluating health care technologies
because it allows us to be confident
that a difference in outcome can be
directly attributed to a difference in
the treatments and not due to some
other factor
39. Health Services Research Unit
RCT strengthsRCT strengths
• Confounding variables minimised
• Only research design which can in
principle yield causal relationships
– can clarify the direction of cause
and effect
• Accepted by EBM school
• Don’t have to know everything about
the participants
40. Health Services Research Unit
RCT limitationsRCT limitations
• Contamination of intervention groups
• Comparable controls
• Problems with blinding
• What to do about attrition?
• Are patients/professionals willing to be
in trial different from ‘refusers’?-
external validity
• Cost!
41. Health Services Research Unit
Other issues in RCTs (1)Other issues in RCTs (1)
• Ethics
• Management issues
• Interim analysis and ‘stopping rules’
– part of ethical concern
– mechanisms to avoid patient harm
– Data Monitoring and Safety
Committee required for trials
Clemens F et al Data monitoring in randomised controlled trials: surveys of recent
practice and policies. Clin Trials 2005;2(1):22-33.
42. Health Services Research Unit
Other issues in RCTs (2)Other issues in RCTs (2)
• A power calculation is essential for the
validity of a trial and will always be
necessary for grant applications and in
publications of the trial (later lecture)
• The methods of randomisation should
always be reported. It is not enough to
say that the patients were randomly
allocated to the treatments. (see
CONSORT)
43. Parallel group (simple) RCTParallel group (simple) RCT
design in practicedesign in practice
Patient eligible for either treatment
Patient gives informed consent
Yes No
Randomise Exclude from trial
Experimental
treatment
Standard
treatment
Standard
treatment
44. Health Services Research Unit
SummarySummary
• “Gold standard” of research designs
• Individual patients are randomly allocated to receive
the experimental treatment (intervention group) or the
standard treatment (control group)
• Maximises the potential for attribution
• Randomisation guards against selection bias between
the two treatment groups
• Standard statistical analysis
• Good internal validity
• May lack generalisability due to highly selected
participants
• Can be costly to set up and conduct, ethical issues
45. Health Services Research Unit
Good study designGood study design
General considerations
• maximise attribution
– Ensure no factor other than the intervention differs
between the intervention and control group
– Random allocation, if adequately carried out, will
in the long run ensure comparable groups with
respect to all factors
• minimise all sources of error
– systematic error (bias)
– random error (chance)
• be practical and ethical
46. Health Services Research Unit
Minimise sources of errorMinimise sources of error
Systematic errors (bias)
• “inaccuracy which is different in its size or direction in
one of the groups under study than the others ”
• Minimise bias by ensuring that the methods used are
applied in the same manner to all subjects
irrespective of which group they belong to.
Random errors (chance)
• “Inaccuracy which is similar in the different groups of
subjects being compared”
• Adequate sample size, accurate methods of
measurement
Elwood (1998)
47. Health Services Research Unit
Study designsStudy designs
• Experimental (Randomised controlled trial)
– A new intervention is deliberately introduced and
compared with standard care
• Quasi-experimental (non-randomised, controlled
before and after)
– Researchers do not have full control over the
implementation of the intervention (“opportunistic
research”)
• Observational (Cohort, case-control, cross-sectional)
– describes current practice
– observed differences cannot be attributed solely to
a “treatment” effect
48. Health Services Research Unit
Evaluation of health careEvaluation of health care
interventionsinterventions
• Randomised controlled trials are considered as the
“gold standard”
• However, some debate over the advantages and
disadvantages of different research designs for
assessing the effectiveness of healthcare
interventions
• Polarised views
– “observational methods provide no useful means of
assessing the value of a therapy” (Doll, 1993)
– RCTs may be unnecessary, inappropriate,
impossible or inadequate (Black, 1996)
• Approaches should be seen as complementary and
not as alternatives (Black, 1996)
– Interpretation of RCTs in terms of
generalisability
49. Health Services Research Unit
Useful/interesting linksUseful/interesting links
• www.jameslindlibrary.org (History)
• www.consort-statement.org (CONSORT)
• www-users.york.ac.uk/~mb55/pubs/pbstnote.htm (All
the stats notes from BMJ)
• www.ctu.mrc.ac.uk (MRC CTU)
• www.rcrt.ox.ac.uk (under construction)
• Doll R. Clinical Trials the 1948 watershe BMJ 1998;317:1217-
1220
• The unpredictability paradox: review of empirical
comparisons of randomised and non-randomised clinical
trials Regina Kunz and Andrew D Oxman BMJ 1998 317:
1185-1190
50. Health Services Research Unit
ReferencesReferences
• Black. Why we need observational studies to
evaluate the effectiveness of health care. BMJ 1996:
312;1215-8
• Crombie. Research in Health Care. 1996
• Doll. Doing more good than harm: the evaluation of
health care interventions. Ann NY Acad Sci
1993:703;310-13
• Elwood M. Critical appraisal of epidemiological
studies and clinical trials. 1998 OUP; Oxford.
• Greenhalgh T. How to read a paper. 2001 BMJ;
London
• Schulz and Grimes. Lancet Epidemiology series.
2002
Editor's Notes
Use blinding in RCTs to avoid biases - nonone knows which treatment is given to the groups of patients so they cant prejudge to effects of the treatment
give definition of a placebo - must be identical in every way
define double blind - ie when no one directly involved knows the treatment status, not patient assessor nor investigator
single blind is where patient does not know
open - everyone knows
No good reason to expect the remaining groups to be equivalent
Remember what I said in the first lecture - the RCT is for answering questions about evaluation of the effectiveness and efficiency of treatments ie how much questions - what is the effect of
- we use different methods to answer other questions, such as why do people in one part of UK appear to have a better out come from a treatment than people in another geographical location.
An RCT does not tell us why something is the in the true sense - ie it will not tell us why aspirin might be better than paracetamol for certain headaches, only that some outcome is better for a group of patients receiving aspirin than the paracetamol patients
- be careful of using the word cause
Read down
confounding variables are those things about the patients which might be resulting in differences between two groups but we may have have no way of determining describing or measuring them properly
It’s the only design which can in principle yield causal relationships (caution - we may never know the nature of that realtionship0 - philosophy of science)
Can clarify but we will never know or prove anything
see philosophy of science
Attrition or drop out
Intention to treat - try to account for all patients who started out at beginning of study - lots drop out - is this telling you something about one of the treatments
Accounting may not be possible - would like to test them before they drop out or die, but cant always!
In that case base an assessment of these patents on the most recent measure you have available
Something about those in agreeing to trial different from rest of population? -affects generalisbaility
contamination - slts giving slt and non slt in rct
surgeon doing both operations
Patients in ward with new advice passing it to those on the other ward
RCT is an experiment - more controlled by its very nature than the chaos of the real world of practice and people
Give examples of bias
selection
sampling
recall
contamination
withdrawl
compliance
measurement bias
observer bias
data dredging
post hoc significance